ACTIVating Resources for the COVID-19 Pandemic: In Vivo Models for Vaccines and Therapeutics.
ACTIVating Resources for the COVID-19 Pandemic: In Vivo Models for Vaccines and Therapeutics.
复制标题
DOI：
10.1016/j.chom.2020.09.016
复制
发表时间：
2020-11-11
影响因子：
30.3
通讯作者：
Haigwood NL
中科院分区：
文献类型：
--
作者：
Hewitt JA;Lutz C;Florence WC;Pitt MLM;Rao S;Rappaport J;Haigwood NL
加速COVID-19治疗干预和疫苗临床前工作组（ACTIV）是由美国国立卫生研究院牵头的公私合作伙伴关系，负责识别、优先考虑和交流SARS-CoV-2临床前资源。审查SARS-CoV-2动物模型数据有助于标准化和协调，并告知知识差距和有限资源的优先次序。迄今为止，已对小鼠、仓鼠、雪貂、豚鼠和非人灵长类动物进行了研究。有几个物种允许SARS-CoV-2复制，通常表现出轻微的疾病并消退，反映了大多数人类COVID-19病例。在一些模型中会出现更严重的疾病，其中一些与高龄有关，这是人类疾病的一个风险因素。这篇综述提供了一个快照，建议用于测试疫苗和治疗方法的模型的适用性，随着我们对COVID-19疾病生物学的理解的提高，这可能会发生变化。COVID-19是一种复杂的疾病，单个模型概括了疾病的某些方面;因此，动物模型的协调和评估势在必行。COVID-19疾病的动物模型得到了迅速发展。休伊特等人代表NIH领导的ACTIV公私合作伙伴关系。将这些小型和大型模型与人类疾病进行比较，并为各类治疗药物和疫苗的临床前测试提出建议。
The Preclinical Working Group of Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), a public-private partnership spearheaded by the National Institutes of Health, has been charged with identifying, prioritizing, and communicating SARS-CoV-2 preclinical resources. Reviewing SARS-CoV-2 animal model data facilitates standardization and harmonization and informs knowledge gaps and prioritization of limited resources. To date, mouse, hamster, ferret, guinea pig, and non-human primates have been investigated. Several species are permissive for SARS-CoV-2 replication, often exhibiting mild disease with resolution, reflecting most human COVID-19 cases. More severe disease develops in a few models, some associated with advanced age, a risk factor for human disease. This review provides a snapshot that recommends the suitability of models for testing vaccines and therapeutics, which may evolve as our understanding of COVID-19 disease biology improves. COVID-19 is a complex disease, and individual models recapitulate certain aspects of disease; therefore, the coordination and assessment of animal models is imperative. Animal models of COVID-19 disease have been rapidly developed. On behalf of the ACTIV public-private partnership led by NIH, Hewitt et al. compare these small and large models to human disease and make recommendations for preclinical testing of various classes of therapeutics and vaccines.
登录
查看更多内容
影响因子：
168.9
作者：
Huang, Chaolin;Wang, Yeming;Cao, Bin
通讯作者：
Cao, Bin
影响因子：
5.4
作者：
Brocato RL;Principe LM;Kim RK;Zeng X;Williams JA;Liu Y;Li R;Smith JM;Golden JW;Gangemi D;Youssef S;Wang Z;Glanville J;Hooper JW
通讯作者：
Hooper JW
影响因子：
56.9
作者：
Chandrashekar, Abishek;Liu, Jinyan;Barouch, Dan H.
通讯作者：
Barouch, Dan H.
影响因子：
16.6
作者：
Deng, Wei;Bao, Linlin;Qin, Chuan
通讯作者：
Qin, Chuan
影响因子：
11.1
作者：
Douam F;Gaska JM;Winer BY;Ding Q;von Schaewen M;Ploss A
通讯作者：
Ploss A